» Articles » PMID: 35327397

Nobiletin Alleviates Ferroptosis-Associated Renal Injury, Inflammation, and Fibrosis in a Unilateral Ureteral Obstruction Mouse Model

Overview
Journal Biomedicines
Date 2022 Mar 25
PMID 35327397
Authors
Affiliations
Soon will be listed here.
Abstract

Nobiletin (Nob), a critical active flavonoid of citrus fruits, has received attention for its superior physical functions, which have shown to improve the progression of diseases. Chronic kidney disease (CKD) is recognized as a global health problem, and its mortality and morbidity rates are worsened with an increased risk of accompanying disorders. In this study, we aimed to elucidate whether Nob treatment ameliorates kidney fibrosis and also to identify the potential signaling networks in a unilateral ureteral obstructive (UUO) mouse model, which was used to mimic the progression of CKD. Six-week-old C57BL/6J mice were orally treated with 50 mg/kg of Nob for 14 constitutive days after UUO surgery. We found that the administration of Nob diminished kidney fibrosis and the expression of EMT markers, ameliorated oxidative stress and ferroptosis-associated injury, and mitigated the inflammatory response in the kidneys of UUO mice. Our results suggested that Nob treatment has antiferroptosis, anti-inflammatory, and antifibrotic effects, improving the progression of CKD in UUO mice. Nob may serve as a potential therapeutic candidate for the improvement of progressive CKD in further studies.

Citing Articles

Fucoxanthin Ameliorates Kidney Injury by CCl-Induced via Inhibiting Oxidative Stress, Suppressing Ferroptosis, and Modulating Gut Microbiota.

Ding Y, Ye J, Liu Y, Zhang S, Xu Y, Yang Z ACS Omega. 2025; 10(7):7407-7421.

PMID: 40028144 PMC: 11865997. DOI: 10.1021/acsomega.4c11437.


Protective Effects of Tormentic Acid on Unilateral Ureteral Obstruction-Induced Renal Injury, Inflammation, and Fibrosis: A Comprehensive Approach to Reducing Oxidative Stress, Apoptosis, and Ferroptosis.

Yang A, Kim J, Gwon M, Kwon H, Leem J, Jeon E Antioxidants (Basel). 2025; 14(1.

PMID: 39857346 PMC: 11762340. DOI: 10.3390/antiox14010013.


Metal-Dependent Cell Death in Renal Fibrosis: Now and in the Future.

Li T, Yu C Int J Mol Sci. 2025; 25(24.

PMID: 39769044 PMC: 11678559. DOI: 10.3390/ijms252413279.


Deciphering ferroptosis in critical care: mechanisms, consequences, and therapeutic opportunities.

Tan R, Ge C, Yan Y, Guo H, Han X, Zhu Q Front Immunol. 2024; 15:1511015.

PMID: 39737174 PMC: 11682965. DOI: 10.3389/fimmu.2024.1511015.


Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.

Touny A, Venkataraman B, Ojha S, Pessia M, Subramanian V, Hariharagowdru S Nutrients. 2024; 16(21).

PMID: 39519465 PMC: 11547603. DOI: 10.3390/nu16213633.


References
1.
Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G . Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discov. 2021; 7(1):193. PMC: 8313570. DOI: 10.1038/s41420-021-00579-w. View

2.
Wu Y, Cheng C, Li Q, Chen J, Lv L, Xu J . The Application of in Breast Cancer and the Mechanism of Its Main Component Nobiletin: A Systematic Review. Evid Based Complement Alternat Med. 2021; 2021:2847466. PMC: 8260297. DOI: 10.1155/2021/2847466. View

3.
Higashi K, Oda T, Kushiyama T, Hyodo T, Yamada M, Suzuki S . Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton). 2010; 15(3):327-35. DOI: 10.1111/j.1440-1797.2009.01253.x. View

4.
Nogueira A, Pires M, Oliveira P . Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. In Vivo. 2017; 31(1):1-22. PMC: 5354133. DOI: 10.21873/invivo.11019. View

5.
Andrade-Oliveira V, Foresto-Neto O, Watanabe I, Zatz R, Camara N . Inflammation in Renal Diseases: New and Old Players. Front Pharmacol. 2019; 10:1192. PMC: 6792167. DOI: 10.3389/fphar.2019.01192. View